Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice